Bayer acquires Perfuse Therapeutics for up to $2.45 billion
Bayer is acquiring Perfuse Therapeutics, a developer of eye disease drugs, in a deal valued at up to $2.45 billion. The agreement includes a $300 million upfront payment, with the remaining amount contingent on achieving development, regulatory, and commercial milestones. This acquisition underscores Bayer's strategic expansion into ophthalmology and its commitment to addressing unmet medical needs in eye care.
Key facts
- Bayer is acquiring Perfuse Therapeutics.
- The deal is valued at up to $2.45 billion.
- Bayer will pay $300 million upfront.
- Remaining payments are tied to milestones.
- Perfuse Therapeutics develops eye disease drugs.
- The acquisition focuses on ophthalmology.
- Milestones include development, regulatory, and commercial targets.
- The deal highlights Bayer's expansion in eye care.
Entities
Institutions
- Bayer
- Perfuse Therapeutics
Sources
- Quartz —